

# UPADHRISH RESERCHEM LLP

LLPIN: AAA-2807

Regd. Office: 4th Floor, Laxmi Towers-II, L.S.C., C-Block, Saraswati Vihar, Delhi-110034

---

## Disclosure under Micro, Small and Medium Enterprises Development Act 2006

We M/s. Upadhrish Reserchem LLP, hereby disclosing as under for 31.03.2022:

ITEM NO.	DISCLOSURES REQUIRED UNDER THE MICRO, SMALL & MEDIUM DEVELOPMENT ACT, 2006
I	Delayed payments due as at the end of each accounting year on account of Principal – <b>Rs. 620,713</b> and Interest Due Thereon – <b>Nil</b>
II	Total Interest Paid on All Delayed Payments During the year under the Provisions Of The Act – <b>Nil</b>
III	Interest due on principal amounts paid beyond the due date during the year but without the interest amounts under this Act – <b>Nil</b>
IV	Interest accrued but not due– <b>Nil</b>
V	Total Interest Due but not paid – <b>Nil</b>

For Upadhrish Reserchem LLP

**Lalit Kumar**  
(Nominee Designated Partner of  
Akums Drugs & Pharmaceuticals Limited)  
DPIN: 07197345

Place: Haridwar  
Date:07.06.2022



*V. P. Gupta & Co.*  
*Chartered Accountants*

## INDEPENDENT AUDITOR'S REPORT

To the Partners of  
Upadhrish Reserchem LLP

### Opinion

We have audited the accompanying financial statements of **Upadhrish Reserchem LLP** ("the entity"), which comprise the Statement of Assets and Liabilities as at 31<sup>st</sup> March, 2022, and the Statement of Profit and Loss and Cash Flow Statement for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information (hereinafter referred to as financial statements).

In our opinion, the accompanying financial statements give a true and fair view of the financial position of the entity as at 31<sup>st</sup> March, 2022, and of its financial performance and its cash flows for the year then ended in accordance with the Accounting Standards issued by the Institute of Chartered Accountants of India (ICAI).

### Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) issued by ICAI. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the entity in accordance with the ethical requirements that are relevant to our audit of the financial statements in India, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### Responsibilities of Management for the Financial Statements

Management (i.e. Partners of LLP) is responsible for the preparation and fair presentation of the financial statements in accordance with the aforesaid Accounting Standards, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

*288, Ghalib Apartments, Parwana Road, Pitampara, Delhi 110034, India*

*Ph. :- 91-11-27020321, 9313675636 Email:- tax@vpguptaandco.com*



In preparing the financial statements, management is responsible for assessing the entity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the entity or to cease operations, or has no realistic alternative but to do so.

Management is also responsible for overseeing the entity's financial reporting process.

### **Auditor's Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify



our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the entity to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the management regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide to the management with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

**For V.P. Gupta & Co.**  
**Chartered Accountants**

(FRN 000699N)



**CA V.P. Gupta**

**Partner**

**M. No.080557**

**Place: Delhi**

**Date: 07.06.2022**

**UIN: 22080557 AKYMPN1066**

**UPADHRISH RESERCHEM LLP**  
**4th Floor, Laxmi Tower-II, LSC, Block-C, Saraswati Vihar, Delhi-110034**  
**STATEMENT OF ASSETS AND LIABILITIES AS AT 31st MARCH,2022**

(Amount in Rs.)

Particulars	Notes	As at March 31, 2022	As at March 31, 2021
<b>I CONTRIBUTION AND LIABILITIES</b>			
<b>1 Partners' funds</b>			
(a) Partner's contribution	1	1,501,000	1,501,000
(b) Partner's current account	2	69,367,842	51,456,205
		<b>70,868,842</b>	<b>52,957,205</b>
<b>2 Non-current liabilities</b>			
(a) Long-term borrowings	3	105,900,000	82,100,000
(b) Deferred tax liabilities(net)		4,871,279	5,468,497
(c) Other long-term liabilities	4	50,000	50,000
(d) Provisions	5	2,278,879	1,433,321
		<b>113,100,158</b>	<b>89,051,818</b>
<b>3 Current liabilities</b>			
(a) Trade payables	6		
-outstanding dues to micro and small enterprises		620,713	1,339,300
-outstanding dues of creditors other than micro and small enterprises		13,107,644	11,323,317
(b) Other current liabilities	7	19,983,658	10,692,334
(c) Short-term provisions	8	502,312	69,622
(d) Current tax liabilities (net)		1,251,020	2,656,394
		<b>35,465,347</b>	<b>26,080,967</b>
<b>TOTAL</b>		<b>219,434,347</b>	<b>168,089,990</b>
<b>II ASSETS</b>			
<b>1 Non-current assets</b>			
(a) Property, plant & equipments and intangible assets			
(i) Tangible assets	9a	96,455,501	99,016,548
(ii) Intangible assets (acquired)	9a	25,030	154,418
(iii) Capital work in progress	9b	88,215,157	35,562,149
(b) Other non-current assets	10	645,460	583,315
		<b>185,341,148</b>	<b>135,316,430</b>
<b>2 Current assets</b>			
(a) Inventories	11	15,052,110	11,038,096
(b) Trade receivables	12	6,456,608	1,987,909
(c) Cash and cash equivalents	13	8,937,155	17,078,933
(d) Other current assets	14	3,647,326	2,634,497
(e) Current tax assets (net of prepaid taxes)		-	34,125
		<b>34,093,199</b>	<b>32,773,560</b>
<b>TOTAL</b>		<b>219,434,347</b>	<b>168,089,990</b>

Significant accounting policies and notes to accounts annexed.

As per our report of even date attached

For V.P. Gupta & Co.

Chartered Accountants  
(FRN 000699N)

  
 V.P. Gupta  
 Chartered Accountants  
 DELHI

Partner

M. No.080557

Place: Delhi

Date: 07.06.2022

For Upadhrish Reserchem LLP

  
  
 S.P. Ojha                      Lalit Kumar

(Des. Partner)

(Rep. of Desg.  
Partner-Akums)

(DIN:00323578)

(DIN:07197345)

Place: Haridwar

Date: 07.06.2022

UDIN: 22080557AKYMPN1666

**UPADHRISH RESERCHEM LLP**  
**4th Floor, Laxmi Tower-II, LSC, Block-C, Saraswati Vihar, Delhi-110034**  
**STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31st MARCH, 2022**

(Amount in Rs.)

Particulars	Notes	For the year ended March 31,2022	For the year ended March 31,2021
<b>Income</b>			
Revenue from operations	15	281,842,342	215,601,537
Other Income	16	1,331,686	604,587
<b>TOTAL</b>		<b>283,174,028</b>	<b>216,206,124</b>
<b>Expenses</b>			
Cost of materials consumed	17	80,387,254	59,950,689
Purchases of stock-in-trade		8,584,065	11,850,722
Changes in inventories of finished goods, work in progress and stock in trade	18	(83,749)	454,607
Employee benefits expense	19	41,453,517	32,943,129
Other expenses	20	29,309,720	18,116,206
Finance costs	21	5,924,742	4,532,723
Depreciation and amortization expense	9a	10,308,299	9,554,253
<b>TOTAL</b>		<b>175,883,848</b>	<b>137,402,329</b>
<b>Profit before taxes(PBT)</b>		<b>107,290,180</b>	<b>78,803,795</b>
<b>Less: Tax expense</b>			
Current tax		38,433,449	27,097,399
Previous Year		86,107	-
Deferred tax		(597,218)	250,191
		<b>37,922,338</b>	<b>27,347,590</b>
<b>Profit after taxes(PAT)</b>		<b>69,367,842</b>	<b>51,456,205</b>
<b>Profit transferred to Partner's Current Account</b>		<b>69,367,842</b>	<b>51,456,205</b>

Significant accounting policies and notes to accounts annexed.

As per our report of even date attached

For V.P. Gupta & Co.  
Chartered Accountants  
(FRN 000699N)

  
CA V.P. Gupta  
Partner  
M. No.080557  
Place: Delhi  
Date: 07.06.2022

For Upadhrish Reserchem LLP

  
S.P. Ojha

(Des. Partner)

(DIN:00323578)

Place: Haridwar




Date: 07.06.2022

  
Lalit Kumar

(Rep. of Desg.  
Partner-Akums)

(DIN:07197345)

UDIN: 22080557 AKYMPN1066

UPADHRISH RESERCHER LLP			
4th Floor, Laxmi Tower-II, LSC, Block-C, Saraswati Vihar, Delhi-110034			
CASH FLOW STATEMENT FOR THE YEAR ENDED 31st MARCH, 2022			
(Amount in Rs.)			
Particulars		2021-22	2020-21
<b>A. Cash Flow from/(used in) Operating Activities</b>			
Net profit before tax		107,290,180	78,803,795
Adjustments			
Add: Depreciation and amortisation		10,308,299	9,554,253
Profit on sale of Property, Plant and Eqt.		(41,532)	(6,370)
Provision for gratuity and leave encashment		1,278,248	160,009
Finance cost		5,924,742	4,532,723
Operating profit before working capital changes		124,759,937	93,044,410
Adjustments for working capital changes			
Inventories		(4,014,014)	2,732,259
Trade Receivables		(4,468,699)	(2,331,391)
Other current assets		(1,074,974)	-
Trade and other payables		10,357,064	7,343,988
Cash generated from operations		125,559,314	100,789,266
Direct taxes paid		(39,890,805)	(22,361,128)
Net Cash from/(used in) Operating Activities	(A)	85,668,509	78,428,138
<b>B. Cash Flow from/(used in) Investing Activities</b>			
Purchase of Property, Plant and Eqt. & Intangible Assets		(7,945,332)	(9,559,239)
Amount spend towards Capital work in progress		(52,653,008)	(22,684,274)
Sale of assets		369,000	381,000
Net Cash from/(used in) Investing Activities	(B)	(60,229,340)	(31,862,513)
<b>C. Cash Flow from/(used in) Financing Activities</b>			
Unsecured loan Recd./((repaid) from/(to) partner (net)		23,800,000	76,100,000
Repaid to partners in current account /Amt. withdrawn by retiring partners		51,456,205	(113,648,434)
Finance cost		(5,924,742)	(4,532,723)
Net Cash from/(used in) Financing Activities	(C)	69,331,463	(42,081,157)
Net Change in Cash and Cash Equivalents	(A+B+C)	94,770,632	4,484,468
Cash and Cash Equivalents (Opening Balance)		17,078,933	12,594,465
Cash and Cash Equivalents (Closing Balance)		8,937,155	17,078,933
Change in Cash and Cash Equivalents		8,141,778	(4,484,468)
<b>Significant accounting policies and notes to accounts annexed.</b>			
<b>Note:</b>			
1. Cash and cash equivalents components are as per note 13			
<b>As per our report of even date attached</b>			
<b>For V.P. Gupta &amp; Co.</b>		<b>For Upadhrish Reserchem LLP</b>	
Chartered Accountants			
(FRN 000699N)			
			
CA V.P. Gupta		S.P. Ojha	
Partner		(Des. Partner)	
M. No.080557		(DIN:00323578)	
Place : Delhi		Place: Haridwar	
Date: 07.06.2022		Date: 07.06.2022	
			
		Lalit Kumar	
		(Rep. of Desg. Partner-Akums)	
		(DIN:07197345)	

UDIN: 22080557 AKYMPN1066

**UPADHRISH RESERCHEM LLP**  
**4th Floor, Laxmi Tower-II, LSC, Block-C, Saraswati Vihar, Delhi-110034**  
**SIGNIFICANT ACCOUNTING POLICIES AND NOTES TO FINANCIAL STATEMENTS**

**I. SIGNIFICANT ACCOUNTING POLICIES**

**a) Basis of preparation of financial statements**

The financial statements are prepared under the historical cost convention in accordance with the generally accepted accounting principles. The LLP follows mercantile system of accounting and recognize significant items of income and expenditure on accrual basis.

The financial statements including notes thereon are presented in Indian rupees, which is the functional currency of the LLP.

**b) Use of significant judgements, estimates and assumptions**

The preparation of financial statements in conformity with generally accepted accounting principles requires partners to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the date of the financial statement and the results of operations during the reporting year ended. Although these estimates are based upon partners' best knowledge of current events and action, actual results could differ from these estimates. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods.

**Significant judgements, estimates and assumptions**

**i.) Taxes**

The LLP has created deferred tax asset/liability on other deductible timing differences. Deferred tax assets/liability are recognized only to the extent that it is probable that the timing differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilised.

**ii.) Property, plant and equipment and intangible assets**

The useful life of plant, property equipment and intangible assets are determined based on past experience of the partners of the expected usage of the asset, the physical wear and tear and technical or commercial obsolescence of the asset. Due to the judgements involved in such estimations, the useful life and residual value are sensitive to the actual usage in future period.



**iii.) Recognition and measurement of defined benefit obligations**

The cost of the leave encashment, defined benefit plan and other post-employment benefits and the present value of such obligation are determined using actuarial valuations. An actuarial valuation involves making various assumptions that may differ from actual developments in the future. These include the determination of the discount rate, future salary increases, mortality rates and attrition rate. Due to the complexities involved in the valuation and its long-term nature, a defined benefit obligation is highly sensitive to changes in these assumptions. All assumptions are periodically reviewed at each reporting date.

**iv.) Provision for litigations and contingencies**

The provision for litigations and contingencies are determined based on evaluation made by the partners of the present obligation arising from past events the settlement of which is expected to result in outflow of resources embodying economic benefits, which involves judgements around estimating the ultimate outcome of such past events and measurement of the obligation amount.

4





**c) Property, plant & equipment and Intangible assets**

(i) Property, plant and equipment are stated at cost, less accumulated depreciation and impairment, if any. Costs directly attributable to acquisition are capitalised until the property, plant and equipment are ready for use, as intended by partners.

(ii) The LLP depreciates property, plant and equipment over their estimated useful lives using the straight-line method. Depreciation on addition to property, plant & equipments is provided on pro-rata basis from the date the assets are ready for intended use. Depreciation on sale/discard from property, plant & equipments is provided for upto the date of sale, deduction or discard of property, plant & equipments as the case may be. The estimated useful lives of assets are as follows:

Particulars	Useful Lives
Building	30 Years
Plant and machinery	15 Years
Laboratory equipments	10 Years
Electrical installation	10 Years
Furniture and fittings	10 Years
Office equipments	5 Years
Computer equipments	3/6 Years

Advances paid towards the acquisition of property, plant and equipment outstanding at date of statement of assets and liabilities date is classified as capital advances under other non-current assets and the cost of assets not put to use before such date are disclosed under 'capital work-in-progress'. Subsequent expenditures relating to property, plant and equipment is capitalized only when it is probable that future economic benefits associated with these will flow to the LLP and the cost of the item can be measured reliably. Repairs and maintenance costs are recognised in the Statement of Profit and Loss when incurred. The cost and related accumulated depreciation are eliminated from the financial statements upon sale or retirement of the asset and the resultant gains or losses are recognised in the Statement of Profit and Loss.

(iii) Leasehold premium paid on leasehold land is amortized over the period of lease.

(iv) Intangible assets (acquired) are stated at cost less accumulated amortization and impairment, if any. Intangible assets are amortized over their respective individual estimated useful lives on a straight-line basis, from the date that they are available for use.

The LLP uses a presumption that the useful life of an intangible asset is five years from the date when the asset is available for use. The cost thereof is amortized over a period of 5 years.

**d) Employees' benefits**


All employee benefits payable wholly within twelve months rendering service are classified as short term employee benefits. Benefits such as salaries, wages, short-term compensated absences, performance incentives etc., and the expected cost of bonus are recognized during the period in which the employee renders related service.

**Gratuity**

The LLP provides for gratuity, a defined retirement benefit, covering eligible employees. The LLP provides a lump-sum payment for gratuity to vested employees at retirement, death, incapacitation or termination of employment, of an amount based on the respective employee's salary and the tenure of employment with the LLP.

Liabilities with regard to the Gratuity are determined by actuarial valuation, performed by an independent actuary, at date of statement of assets and liabilities using the projected unit credit(PUC) method. The LLP recognizes the net obligation of a defined benefit plan in its statement of assets and liability as an liability.

 5





**Provident fund**

Retirement benefits, in the form of Provident Fund, is defined as a contribution plan and the contribution is charged to the Statement of Profit and Loss of the year when the contribution to the fund is due.

**Compensated absences**

The LLP has a policy on compensated absences which are both accumulating and non-accumulating in nature. The expected cost of accumulating compensated absences is determined by actuarial valuation performed by an independent actuary at date of Statement of assets and liabilities using projected unit credit(PUC) method on the additional amount expected to be paid/availed as a result of the unused entitlement that has accumulated at the date of statement of assets and liabilities. Expense on non-accumulating compensated absences is recognized in the period in which the absences occur.

**e) Valuation of inventories**

Inventories are valued on uniform basis as under:

- (i) Raw Material - at cost on FIFO basis.
- (ii) Packing Material - at cost on FIFO basis
- (iii) Finished goods - at estimated cost or net realizable value, whichever is less.
- (iv) Traded goods - at cost or net realizable value, whichever is less. Cost is computed by following FIFO basis.
- (v) Inventory of stores values at estimated cost.

**f) Provisions and contingent liabilities**

Provisions are recognized in respect of obligations where, based on the evidence available, their existence at the date of Statement of assets and liabilities is considered probable.

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the LLP or a present obligation that is not recognised because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases, where there is a liability that cannot be recognised because it cannot be measured reliably. The LLP does not recognize a contingent liability but discloses its existence in the financial statements.

**g) Revenue recognition**

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the LLP and the revenue can be reliably measured. The following recognition criteria is adopted for:

**Sale of goods**

Revenue from sale of goods is recognised when all the significant risks and rewards of ownership of the goods have been passed to the buyer, usually on delivery of the goods. The amount recognised as sale are also net of discounts. The LLP collects goods and service tax (GST) on behalf of the Government and, therefore, these are not economic benefits flowing to the LLP. Hence, they are excluded from revenue.

**Sale of services**

Revenues from services are recognized as and when services are rendered. The LLP collects service tax and goods and service tax(GST) on behalf of the government and, therefore, it is not an economic benefit flowing to the LLP. Hence, it is excluded from revenue.



**Interest**

Interest income is recognised as and when due on the time proportion basis. Interest income is included under the head "other income" in the Statement of profit and loss.

**h) Borrowing costs**

Borrowing costs includes interest and ancillary costs incurred in connection with the arrangement of borrowings. Borrowings costs relating to acquisition of assets till commencement of production, are capitalised. Other borrowings costs are recognized as expenses in the period in which these are incurred.

**i) Taxes**

Provision for taxation comprises of income tax liability on the profits for the year chargeable to tax and Deferred tax resulting from timing differences between book and tax profits. The Deferred tax assets/liability is provided in accordance with the Accounting Standard -22 (AS-22) "Accounting for taxes on income" issued by ICAI.

**j) Cash and cash equivalents**

Cash flows are reported using the indirect method, whereby profit for the period is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future operating cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the LLP are segregated.

Cash and cash equivalents for the purposes of cash flow statement comprise cash at bank and in hand and bank deposit with banks where original maturity is three months or less.

**k) Government grant and subsidy**

Government grant and subsidy from the government are recognized when there is reasonable assurance that (i) the LLP will comply with the conditions attached to them, and (ii) the grant/subsidy will be received.

When the grant or subsidy relates to income, it is recognized as income on a systematic basis in the statement of profit and loss over the periods, which they are intended to compensate.

**(l) Leases****Where the LLP is Lessee****Operating Lease**

Lease payments under operating leases are recognized as an expense on a straight line basis in the Statement of Profit and Loss over the lease term.



**UPADHRISH RESERCHEM LLP**  
4th Floor, Laxmi Tower-II, LSC, Block-C, Saraswati Vihar, Delhi-110034

**II. Notes to FINANCIAL STATEMENTS**

**Note-1 Partner's contribution**

Partner's Name	As at 31st March, 2022				As at 31st March, 2021				(Amount in Rs.)
	Opening Balance	Addition during the year	Withdrawals during the year	Closing Balance	Opening Balance	Addition during the year	Withdrawals during the year	Closing Balance	
Mr. S.P. Ojha	1,000	-	-	1,000	1,000	-	-	1,000	1,000
Akums Drugs & Pharmaceuticals Ltd.	1,500,000	-	-	1,500,000	1,500,000	-	-	1,500,000	1,500,000
<b>Total Partner's Contribution</b>	<b>1,501,000</b>	<b>-</b>	<b>-</b>	<b>1,501,000</b>	<b>1,501,000</b>	<b>-</b>	<b>-</b>	<b>1,501,000</b>	<b>1,501,000</b>

**Note-2 Partner's current account**

Partner's Name	Balances as at 31st March, 2022				Balances as at 31st March, 2021			
	Balance as at 1st April, 2021	Profit for the year	Withdrawals during the year	Balance as at 31st March, 2022	Balance as at 1st April, 2020	Profit for the year	Withdrawals during the year	Balance as at 31st March, 2021
Mr. S.P. Ojha	34,281	46,214	(34,281)	46,214	32,013	34,281	(32,013)	34,281
Akums Drugs & Pharmaceuticals Ltd.	51,421,924	69,321,628	(51,421,924)	69,321,628	113,616,421	51,421,924	(113,616,421)	51,421,924
<b>Total Partner's Current account</b>	<b>51,456,205</b>	<b>69,367,842</b>	<b>(51,456,205)</b>	<b>69,367,842</b>	<b>113,648,434</b>	<b>51,456,205</b>	<b>(113,648,434)</b>	<b>51,456,205</b>

*(Signature)*



**UPADHRISH RESERCHEM LLP**

**Note-9a Property, plant & equipment and Intangible assets**

Description of Assets	Gross					Accumulated Depreciation		Net		
	As at 31.03.2021	Additions	Disposal	As at 31.03.2022	Upto 31.03.2021	For the year	Disposal	Upto 31.03.2022	As at 31.03.2022	As at 31.03.2021
<b>Tangible</b>										
Leasehold Land	16,669,450	-	-	16,669,450	1,373,685	185,216	-	1,558,901	15,110,549	15,295,765
Building	27,175,322	-	-	27,175,322	6,196,918	845,924	-	7,042,842	20,132,480	20,978,404
Plant and Machinery	27,677,996	6,183,817	-	33,861,813	10,009,688	1,908,500	-	11,918,188	21,943,625	17,668,308
Laboratory Equipments	57,298,318	1,332,533	-	58,630,851	17,200,153	6,053,312	-	23,253,465	35,377,386	40,098,165
Electrical Installation	4,120,372	227,705	660,000	3,688,077	1,998,296	380,226	332,532	2,045,990	1,642,087	2,122,076
Furniture and Fittings	2,223,990	25,853	-	2,249,843	744,372	236,765	-	981,137	1,268,706	1,479,618
Office Equipments	2,619,392	65,967	-	2,685,359	1,888,983	313,310	-	2,202,293	483,066	730,409
Computer Equipments	2,027,990	109,457	-	2,137,447	1,384,187	255,658	-	1,639,845	497,602	643,803
<b>Total</b>	<b>139,812,830</b>	<b>7,945,332</b>	<b>660,000</b>	<b>147,098,162</b>	<b>40,796,282</b>	<b>10,178,911</b>	<b>332,532</b>	<b>50,642,661</b>	<b>96,455,501</b>	<b>99,016,548</b>
<b>Intangible(acquired)</b>										
Computer Software	1,067,326	-	-	1,067,326	912,908	129,388	-	1,042,296	25,030	154,418
<b>Total</b>	<b>1,067,326</b>	<b>-</b>	<b>-</b>	<b>1,067,326</b>	<b>912,908</b>	<b>129,388</b>	<b>-</b>	<b>1,042,296</b>	<b>25,030</b>	<b>154,418</b>
<b>Grand Total</b>	<b>140,880,156</b>	<b>7,945,332</b>	<b>660,000</b>	<b>148,165,488</b>	<b>41,709,190</b>	<b>10,308,299</b>	<b>332,532</b>	<b>51,684,957</b>	<b>96,480,531</b>	<b>99,170,966</b>
Previous Year figures	131,808,280	9,559,239	487,363	140,890,156	32,267,670	9,554,253	112,733	41,709,190	99,170,966	99,540,610

**9b. Capital work-in-progress**

Particulars	Amount(Rs.)
As at 1 April 2020	12,877,875
Add: Additions during the year	22,684,274
Less: Capitalised during the year	-
<b>As at 31 March 2021/ 1 April 2021</b>	<b>35,562,149</b>
Add: Additions during the year	52,653,008
Less: Capitalised during the year	-
<b>As at 31 March 2022</b>	<b>88,215,157</b>



*(Handwritten signature)*

**UPADHRISH RESERCHEM LLP**


<b>Note-3 Long-term borrowings</b> <span style="float:right">(Amount in Rs.)</span>		
<b>Particulars</b>	<b>As at March 31, 2022</b>	<b>As at March 31, 2021</b>
<b>Loans and advances from related parties(partner)</b>		
<i>Unsecured</i>		
-Akums Drugs & Pharmaceuticals Ltd	105,900,000	82,100,000
Interest @ 7% p.a. (Previous year -Interest @ 8% p.a.)		
<b>Total</b>	<b>105,900,000</b>	<b>82,100,000</b>
<b>Note-4 Other long-term liabilities</b> <span style="float:right">(Amount in Rs.)</span>		
<b>Particulars</b>	<b>As at March 31, 2022</b>	<b>As at March 31, 2021</b>
Security received	50,000	50,000
<b>Total</b>	<b>50,000</b>	<b>50,000</b>
<b>Note-5 Provisions-Non Current</b> <span style="float:right">(Amount in Rs.)</span>		
<b>Particulars</b>	<b>As at March 31, 2022</b>	<b>As at March 31, 2021</b>
<b>Provision for employee benefits</b>		
Gratuity (unfunded)	1,753,836	1,072,968
Leave encashment (unfunded)	525,043	360,353
<b>Total</b>	<b>2,278,879</b>	<b>1,433,321</b>
<b>Note-6 Trade payable</b> <span style="float:right">(Amount in Rs.)</span>		
<b>Particulars</b>	<b>As at March 31, 2022</b>	<b>As at March 31, 2021</b>
-Outstanding dues of micro and small enterprises	620,713	1,339,300
-Outstanding dues of other than micro and small enterprises	13,107,644	11,323,317
<b>Total</b>	<b>13,728,357</b>	<b>12,662,617</b>
<b>Note-7 Other current liabilities</b> <span style="float:right">(Amount in Rs.)</span>		
<b>Particulars</b>	<b>As at March 31, 2022</b>	<b>As at March 31, 2021</b>
Employee payable	4,418,869	3,930,971
Statutory dues	2,826,889	2,649,638
Payable for capital goods	12,628,925	4,065,376
Advance Received from Customers	108,975	46,349
<b>Total</b>	<b>19,983,658</b>	<b>10,692,334</b>
<b>Note-8 Provisions- Current</b> <span style="float:right">(Amount in Rs.)</span>		
<b>Particulars</b>	<b>As at March 31, 2022</b>	<b>As at March 31, 2021</b>
Gratuity (unfunded)	371,825	47,205
Leave encashment (unfunded)	130,487	22,417
<b>Total</b>	<b>502,312</b>	<b>69,622</b>



<b>Note-10 Other non-current assets</b>			<b>(Amount in Rs.)</b>
<b>Particulars</b>	<b>As at March 31, 2022</b>	<b>As at March 31, 2021</b>	
FDR with accrued interest	96,251	85,551	
Security deposit with Govt. dept. and others	352,660	242,155	
Security deposit with supplier	120,000	120,000	
Prepaid Expenses	76,549	135,609	
<b>Total</b>	<b>645,460</b>	<b>583,315</b>	
<b>Note-11 Inventories</b>			<b>(Amount in Rs.)</b>
<b>Particulars</b>	<b>As at March 31, 2022</b>	<b>As at March 31, 2021</b>	
Raw materials (including stock-in-transit)	12,910,945	10,075,111	
Packing materials	597,074	280,624	
Traded goods	133,455	49,706	
Store & spare parts	1,410,636	632,655	
<b>Total</b>	<b>15,052,110</b>	<b>11,038,096</b>	
<b>Note-12 Trade receivables</b>			<b>(Amount in Rs.)</b>
<b>Particulars</b>	<b>As at March 31, 2022</b>	<b>As at March 31, 2021</b>	
<b>(Unsecured, considered good unless otherwise stated)</b>			
Trade receivables	6,456,608	1,987,909	
<b>Total</b>	<b>6,456,608</b>	<b>1,987,909</b>	
<b>Note-13 Cash &amp; cash equivalents</b>			<b>(Amount in Rs.)</b>
<b>Particulars</b>	<b>As at March 31, 2022</b>	<b>As at March 31, 2021</b>	
Balance with the scheduled Banks	8,863,343	16,984,029	
Cash in hand	73,812	94,904	
<b>Total</b>	<b>8,937,155</b>	<b>17,078,933</b>	
<b>Note-14 Other current assets</b>			<b>(Amount in Rs.)</b>
<b>Particulars</b>	<b>As at March 31, 2022</b>	<b>As at March 31, 2021</b>	
Prepaid expenses	575,553	376,310	
Advance to creditors/others	1,801,039	1,451,827	
Capital advances	1,138,809	786,459	
Balance with Government authorities	43,000	-	
Other Current assets	88,925	19,901	
<b>Total</b>	<b>3,647,326</b>	<b>2,634,497</b>	



<b>Note-15 Revenue from operations</b>			<b>(Amount in Rs.)</b>
<b>Particulars</b>	<b>For the year ended March 31,2022</b>	<b>For the year ended March 31,2021</b>	
<b>(a) Sale of goods</b>			
Sale of goods manufactured	152,769,888	108,607,315	
Sale of goods traded	10,874,277	14,385,197	
Sale of other	-	59,315	
<b>Total (a)</b>	<b>163,644,165</b>	<b>123,051,827</b>	
<b>(b) Supply of services</b>			
Job work receipts and instrumentation service	5,943,339	4,511,446	
Calibration charges	16,975,310	11,656,580	
Testing charges	93,453,362	75,413,519	
<b>Total (b)</b>	<b>116,372,011</b>	<b>91,581,545</b>	
<b>(c) Other operating Income</b>			
Sale of Scrap	1,826,166	968,165	
<b>Total (c)</b>	<b>1,826,166</b>	<b>968,165</b>	
<b>Total (a+b+c)</b>	<b>281,842,342</b>	<b>215,601,537</b>	
<b>Note-16 Other income</b>			<b>(Amount in Rs.)</b>
<b>Particulars</b>	<b>For the year ended March 31,2022</b>	<b>For the year ended March 31,2021</b>	
Interest received	313,538	40,359	
Profit on sale of property, plant and equipment	41,532	6,370	
Government grants	164,425	186,813	
Misc. Income	812,191	371,045	
<b>Total</b>	<b>1,331,686</b>	<b>604,587</b>	
<b>Note-17 Materials consumed</b>			<b>(Amount in Rs.)</b>
<b>Particulars</b>	<b>For the year ended March 31,2022</b>	<b>For the year ended March 31,2021</b>	
Opening stock (including stock-in-transit)	10,355,735	12,610,299	
Add: Purchases	83,539,538	57,696,125	
	93,895,273	70,306,424	
Less: Closing stock (including stock-in-transit)	13,508,019	10,355,735	
<b>Total</b>	<b>80,387,254</b>	<b>59,950,689</b>	
<b>Note-18 Changes in inventories of finished goods, work in progress and Stock in trade</b>			<b>(Amount in Rs.)</b>
<b>Particulars</b>	<b>For the year ended March 31,2022</b>	<b>For the year ended March 31,2021</b>	
<b>Stock in trade</b>			
Opening Stock	49,706	504,313	
Less: Closing Stock	133,455	49,706	
<b>Total</b>	<b>(83,749)</b>	<b>454,607</b>	




<b>Note-19 Employee benefits expense</b>			<b>(Amount in Rs.)</b>
<b>Particulars</b>	<b>For the year ended March 31,2022</b>	<b>For the year ended March 31,2021</b>	
Salaries, wages and other benefits	37,020,127	30,077,811	
Contribution to:			
Provident Fund	2,203,395	1,835,120	
ESIC	406,597	325,422	
Gratuity (provision)	1,045,683	135,881	
Leave encashment (provision)	272,760	90,052	
Staff welfare expenses	504,955	478,843	
<b>Total</b>	<b>41,453,517</b>	<b>32,943,129</b>	
<b>Note-20 Other expenses</b>			<b>(Amount in Rs.)</b>
<b>Particulars</b>	<b>For the year ended March 31,2022</b>	<b>For the year ended March 31,2021</b>	
Short term leases	141,600	141,600	
Consumption of stores and spare parts	4,501,591	3,315,977	
Power expenses	9,295,903	5,310,438	
Repairs & maintenance -machinery	8,344,206	4,267,577	
Conveyance expenses	558	12,780	
Fees & subscription	1,061,786	214,926	
Legal & professional expenses	42,200	14,450	
Printing & stationery expenses	486,918	416,519	
Postage & telephone expenses	17,309	13,107	
General repairs & maintenance	2,307,633	1,854,624	
Bank charges	60,110	5,465	
Cartage expenses (incl. loading expense)	106,913	76,434	
Security expenses	1,167,058	1,002,165	
Other expenses	1,277,481	1,088,263	
Insurance expenses	473,454	354,381	
Payment to auditors ( note 25)	25,000	27,500	
<b>Total</b>	<b>29,309,720</b>	<b>18,116,206</b>	
<b>Note-21 Finance Cost</b>			<b>(Amount in Rs.)</b>
<b>Particulars</b>	<b>For the year</b>	<b>For the year</b>	
Interest on loan	5,303,650	4,219,375	
Interest paid on income tax	621,092	313,348	
<b>Total</b>	<b>5,924,742</b>	<b>4,532,723</b>	



**UPADHRISH RESERCHEM LLP**

**NOTES TO FINANCIAL STATEMENTS**

**22. Contingent Liability (not provided for)**

There is no claim against the LLP, which is to be acknowledged as a debt and there is no other contingent liabilities.

**23. Capital and Other Commitments**

(Amount in Rs.)

Particulars	2021-22	2020-21
Estimated amount of contracts remaining to be executed on capital account and not provided for (net of advances)	4,854,827	10,597,482
<b>Total</b>	<b>4,854,827</b>	<b>10,597,482</b>

24. In the opinion of the partners and to the best of the knowledge and belief, the value on realisation of loans, advances and current assets in the ordinary course of business will not be less than the amount at which they are stated in statement of assets and liabilities.

**25. Payment to auditors**

(Amount in Rs.)

Particulars	2021-22	2020-21
as an Auditor		
Audit fees	20,000	20,000
Tax audit fees	5,000	5,000
Other services	-	2,500
<b>Total</b>	<b>25,000</b>	<b>27,500</b>

**26.a. Details of Opening Stocks & Production:**

Product	Unit	2021-22				2020-21		
		Stock		Production	Stock		Production	
		Qty	Value (Rs.)	Qty	Qty	Value (Rs.)	Qty	
LDPE Granules	Kg	-	-	287,981	-	-	245,931	
Ayurvedic Extract	Ltrs.	-	-	272,882	-	-	217,969	
Polymer Stereo	Nos.	-	-	80,018	-	-	68,121	
Plastic Tray	Nos.	-	-	3,945,539	-	-	717,400	
Ingredients	Kg	-	-	176,413	87	41,031	140,210	
Others		-	-	-	-	-	-	
<b>Total</b>		<b>-</b>	<b>-</b>	<b>4,762,833</b>	<b>87</b>	<b>41,031</b>	<b>1,389,631</b>	

**b. Details of Sales & Closing Stocks:**

Product	Unit	2021-22				2020-21			
		Sale		Stock		Sale		Stock	
		Qty	Value (Rs.)	Qty	Value (Rs.)	Qty	Value (Rs.)	Qty	Value (Rs.)
LDPE Granules	Kg	287,981	28,041,416	-	-	245,931	16,901,450	-	-
Ayurvedic Extract	Ltrs.	272,882	27,199,650	-	-	217,969	18,910,418	-	-
Polymer Stereo	Nos.	80,018	800,180	-	-	68,121	681,210	-	-
Plastic Tray	Nos.	3,945,539	4,568,166	-	-	717,400	489,613	-	-
Ingredients	Kg	176,413	92,160,477	-	-	140,297	71,624,624	-	-
Others		-	-	-	-	59,315	-	-	-
<b>Total</b>		<b>4,762,833</b>	<b>152,769,888</b>	<b>-</b>	<b>-</b>	<b>1,389,718</b>	<b>108,666,630</b>	<b>-</b>	<b>-</b>



c. Details of Consumption of Materials:					
Particulars	Unit of Qty	2021-22		2020-21	
		Qty	Value (Rs.)	Qty	Value (Rs.)
Plastics	Kg	137,466	6,178,021	246,342	11,684,278
Crude Herbs	Kg	154,069	12,514,516	101,573	5,606,724
Polymer Sheets	Nos.	72	208,870	67	192,665
Bulk Drugs & Excipients	Kg/Nos.	376,184	59,965,420	147,818	41,413,337
Other Packing Materials	Nos./Kg	39,268	1,520,427	21,611	1,053,485
<b>Total</b>		<b>707,079</b>	<b>80,387,254</b>	<b>517,411</b>	<b>59,950,689</b>

d. Details of goods traded:					
Particulars	Unit of Qty	Opening Stocks			
		2021-22		2020-21	
		Qty	Value (Rs.)	Qty	Value (Rs.)
Bulk Drugs/Crude Herbs	Kg	179	49,706	199	218,565
Packing Materials	Nos/Kg	-	-	144,803	244,717
<b>Total</b>		<b>179</b>	<b>49,706</b>	<b>145,002</b>	<b>463,282</b>

Particulars	Unit of Qty	2021-22					
		Purchases		Sales		Closing Stock	
		Qty	Value (Rs.)	Qty	Value (Rs.)	Qty	Value (Rs.)
Bulk Drugs/Crude Herbs	Kg	30,033	8,212,838	29,923	10,442,724	289	120,946
Packing Materials	Nos/Kg	21,384	371,227	21,302	431,553	82	12,509
<b>Total</b>		<b>51,417</b>	<b>8,584,065</b>	<b>51,225</b>	<b>10,874,277</b>	<b>371</b>	<b>133,455</b>

Particulars	Unit of Qty	2020-21					
		Purchases		Sales		Closing Stock	
		Qty	Value (Rs.)	Qty	Value (Rs.)	Qty	Value (Rs.)
Bulk Drugs/Crude Herbs	Kg	269,081	10,831,930	269,101	13,069,699	179	49,706
Packing Materials	Nos/Kg	498,803	1,018,782	643,606	1,315,498	-	-
<b>Total</b>		<b>767,884</b>	<b>11,850,722</b>	<b>912,707</b>	<b>14,385,197</b>	<b>179</b>	<b>49,706</b>

27. The expenditure in foreign exchange during the year is Rs 1,31,11,670 /- (Previous Year Rs. Nil ) towards import of Laboratory Equipments. There is no earning in foreign exchange during the year (Previous Year Rs. Nil ).

#### 28. Employees Benefits

##### I Details of employees benefits

##### A. Defined Contribution Plan

The LLP contribute for Provident fund, a defined contribution plan, covering the eligible employees. The LLP has recognised the following amount in statement of profit and loss.

(Amount in Rs.)

S. No.	Particulars	2021-22	2020-21
(a)	Employer's contribution to Provident fund	2,203,395	1,835,120

##### B. Defined benefit plan

The LLP provide gratuity, a defined benefit plan covering the eligible employees. The following provisions towards gratuity liability based on the projected unit credit (PUC) actuarial method as per actuarial valuation have been made by the LLP:

(Amount in Rs.)

S. No.	Particulars	2021-22	2020-21
(a)	Provisions towards Gratuity	2,125,661	1,120,173

The following assumptions are taken

(i)	Discount Rate	7.18%	6.79%
(ii)	Future Salary Increase	5.50%	5.50%
(iii)	Expected rate of return on plan assets	N.A	N.A

The details of the expenses recognised in Statement of Profit and Loss and accumulated liabilities in the Statement of assets and liabilities as at 31.03.2022 are as under:

(Amount in Rs.)

(i)	Expenses recognised in Statement of Profit & Loss	2021-22	2020-21
(a)	Service Cost	502,258	368,296
(b)	Interest Cost	76,060	71,026
(c)	Net actuarial (gain)/loss recognised in the year	467,365	(303,441)
(d)	Expenses recognised in the Statement of Profit and Loss	<b>1,045,683</b>	<b>135,881</b>

*[Handwritten Signature]*

*[Handwritten Signature]*



(Amount in Rs.)			
(II)	Liabilities recognised in Statement of asset and liabilities	2021-22	2020-21
(a)	Present value of the obligation as at the beginning of the year	1,120,173	1,046,045
(b)	Expenses as above	1,045,663	135,881
(c)	Benefits Paid	(40,195)	(61,753)
(d)	Re-measurement	-	-
(e)	Present value of the obligation as at 31.03.2022	2,125,661	1,120,173

(Amount in Rs.)			
(III)	Change in present value of obligation	2021-22	2020-21
(a)	Present value of the obligation as at the beginning of the year	1,120,173	1,046,045
(b)	Interest Cost	76,060	71,026
(c)	Current Service cost	502,158	368,296
(d)	Contribution paid to the Fund	-	-
(e)	Benefits paid	(40,195)	(61,753)
(f)	Re-measurement	-	-
(g)	Actuarial (gain)/loss on obligation	467,365	(303,441)
(h)	Present value of the obligation as at the end of year	2,125,661	1,120,173

(IV) Change in fair value of plan assets  
There are no plan assets against the aforesaid liability. Therefore, the return of change in fair value of plan assets is not given.

**(C) Compensated absences**

The following provisions towards compensated absences (i.e. leave encashment) based on the projected unit credit (PUC) actuarial method as per actuarial valuation have been made by the LLP:

(Amount in Rs.)			
S. No.	Particulars	2021-22	2020-21
(a)	Provision towards Leave encashment	655,530	382,770

The following assumptions are taken

(i)	Discount Rate	7.18%	6.79%
(ii)	Future Salary increase	5.50%	5.50%
(iii)	Expected rate of return on plan assets	N.A	N.A


The details of the expenses recognised in Statement of Profit and Loss and as accumulated liabilities in the Statement of asset and liabilities as at 31.03.2022 is as under:

(Amount in Rs.)			
(I)	Expenses recognised in Statement of Profit and Loss	2021-22	2020-21
(a)	Current Service Cost	165,105	193,941
(b)	Past Service Cost	-	-
(c)	Interest Cost	25,990	20,159
(d)	Net actuarial (gain)/loss recognised in the year	81,665	(124,048)
(e)	Expenses recognised in the Statement of Profit & Loss	272,760	90,052

(Amount in Rs.)			
(II)	Liabilities recognised in Statement of assets and liabilities	2021-22	2020-21
(a)	Present value of the obligation as at the beginning of the year	382,770	296,889
(b)	Interest Cost	25,990	20,159
(c)	Current Service cost	165,105	193,941
(d)	Net actuarial (gain)/loss recognised in the year	81,665	(124,048)
(e)	Benefits Paid	-	(4,171)
(f)	Present value of the obligation as at 31.03.2022	655,530	382,770

(Amount in Rs.)			
(III)	Change in present value of obligation	2021-22	2020-21
(a)	Present value of the obligation as at the beginning of the year	382,770	296,889
(b)	Acquisition adjustment	-	-
(c)	Interest Cost	25,990	20,159
(d)	Contribution to the Fund	-	-
(e)	Current Service cost	165,105	193,941
(f)	Benefits paid	-	(4,171)
(g)	Actuarial (gain)/loss on obligation	81,665	(124,048)
(h)	Present value of the obligation as at the end of year	655,530	382,770

(IV) Change in fair value of plan assets  
There are no plan assets against the aforesaid liability. Therefore, the return of change in fair value of plan assets is not given.


II. Employees benefits cost includes		(Amount in Rs.)	
Particulars	2021-22	2020-21	
Salaries and bonus	38,204,439	30,972,128	
Defined contribution plan	2,203,395	1,835,120	
Defined benefit plan	1,045,663	135,881	
<b>Total</b>	<b>41,453,517</b>	<b>32,943,129</b>	
<b>29. Related party disclosures</b>			
Related party disclosures, as required by Accounting Standard-18 issued by ICAI, are as below:			
A. Relationship			
(i) Partners of the LLP Akums Drugs & Pharmaceuticals Ltd and Shri S.P. Ojha.			
(ii) KMP of Partner of the LLP Shri Sandeep Jain			
(iii) Concern in which Partner interested Akumenis Healthcare Ltd, Maxcure Nutravedics Ltd, Malik Lifesciences Pvt. Ltd, Pure & Cure Healthcare Pvt. Ltd, Sarvagunaushdhi (P) Ltd, May and Baker Pharmaceuticals Ltd., Plenteous Pharmaceuticals Limited, Akums Healthcare Ltd And Akums Lifesciences Ltd (w.e.f. 12.01.2021)			
(iv) Concern controlled directly or indirectly by KMP of Partner Cure Sure Pharma			
B. During the current year, following transactions were carried out with the related parties in the ordinary course of business:			
Nature of transactions	2021-22 (Rs.)	2020-21 (Rs.)	
<b>A. Partners of the LLP</b>			
<b>Partner-S.P. OJHA</b>			
Remuneration paid	1,757,753	1,635,744	
Share in Profit	46,214	34,281	
<b>Partner-Akums Drugs &amp; Pharmaceuticals Ltd</b>			
Sales of goods	31,221,071	27,464,876	
Sales of others	-	17,904	
Sales of fixed assets	-	381,000	
Receipt of job charges, testing and calibration charges	46,248,753	41,568,474	
Reimbursement of Expenses received	1,080	-	
Purchase of goods	14,085,177	11,582,131	
Purchase of fixed assets	-	5,139,913	
Expenses paid	295,773	587,984	
Reimbursement of Expenses paid	612,005	-	
Share in Profit	69,321,628	51,421,924	
Loan repaid	26,200,000	23,900,000	
Loan Obtained	50,000,000	100,000,000	
Interest paid on loan	5,303,650	4,219,375	
<b>B. Rent paid to KMP of partner</b>			
	141,600	141,600	
<b>C. Concerns in which partner is interested</b>			
<b>(i) Maxcure Nutravedics Ltd</b>			
Sales of goods	32,483,587	30,084,020	
Receipt of job charges, testing and calibration charges	14,302,501	765,771	
Sales of others	-	11,199	
Reimbursement of Expenses received	2,500	-	
Purchase of goods	5,703,433	7,493,574	
Expenses paid	81,862	80,689	
<b>(ii) Malik Lifesciences Pvt. Ltd</b>			
Sales of goods	2,320,635	1,571,875	
Receipt of job charges, testing and calibration charges	8,633,479	3,952,749	
Sales of others	-	62,548	
Purchase of goods	1,721,050	6,733,767	
Purchase of assets	-	1,986,000	
Expenses paid	76,539	63,180	
<b>(iii) Pure &amp; Cure Healthcare Pvt. Ltd</b>			
Sales of goods	66,671,092	51,410,783	
Receipt of job charges, testing and calibration charges	41,492,333	35,586,254	
Sales of others	-	53,454	
Purchase of goods	3,447,670	1,148,366	
Purchase of fixed assets	520,500	788,328	
Expenses paid	5,855	33,020	



(iv) Sarvagunaushdhi (P) Ltd		
Sales of goods	-	59,315
Expenses paid	11,778	12,415
(v) Akums Healthcare Ltd.		
Sales of goods	6,850	5,760
Receipt of job charges, testing and calibration charges	2,816,237	
(vi) Akumentis Healthcare Ltd		
Receipt of testing charges	1,628,530	1,066,170
(vii) Plenteous Pharmaceuticals Ltd		
Sales of goods	-	20
Receipt of testing charges	16,950	9,900
Expenses received	-	831
(viii) Akums Lifesciences Ltd		
Receipt of job charges, testing and calibration charges	87,000	95,600
Sales of fixed assets	369,000	
<b>D. Entity controlled by KMP of Partner of the LLP</b>		
(i) Cure Sure Pharma		
Sale of goods	286,525	660,800
Receipt of testing charges	892,742	997,416
<b>Amount Outstanding - Receivables</b>		
Akumentis Healthcare Ltd	257,971	125,008
Akums Lifesciences Limited	450,732	111,374
Akums Healthcare Limited	19,440	-
Akums Drugs & Pharmaceuticals Ltd.	814,859	125,430
Maxcure Nutravedics Ltd.	113,987	495,466
Pure & Cure Healthcare P Ltd.	4,737,792	1,112,896
<b>Amount Outstanding - Payable</b>		
Akums Drugs & Pharmaceuticals Ltd.	-	46,158
Malik Lifesciences Ltd.	14,469	-
<b>Amount outstanding - Loan payable</b>		
Akums Drugs & Pharmaceuticals Ltd.	105,900,000	82,100,000

30. In accordance with Accounting Standard 22 "Accounting for Taxes on Income" issued by ICAI, LLP has accounted for deferred taxes.

31. As agreed between partners, Interest on partners contribution/credit lying in partner's current account has not been provided for the year as decided among partners.

32. During the year, LLP has received grant of Rs. 1,32,206/- (Rs.1,32,813/-) from government under the scheme "Pradhan Mantri Rojgar Protsahan Yojana (PMRPY)". Under this scheme, Government of India is giving incentive to employers for generation of new employment. The Government of India is paying the full employer's contribution towards EPF & EPS for the new employment generated by the entity w.e.f 01.04.2018. The LLP has accounted for such grant under the head other income in the statement of profit and loss.

33. All figures have been rounded-off to the nearest rupee and figures in brackets relate to previous year.

34. Previous year figures have been regrouped /rearranged wherever considered necessary for comparison.

As per our report of even date attached

For V.P. Gupta & Co.  
Chartered Accountants  
(FRN:000699N)



Place: Delhi

Date: 07.06.2022

U.DIN: 22080557 AKYMPW 1666

For Upadhrish Reserchem LLP

S.P. Ojha  
(Designated Partner)  
(DIN:00323578)

Place: Haridwar

Date: 07.06.2022

Lalit Kumar  
(Rep. of Desg. Partner-Akums)  
(DIN:07197345)